Voreloxin single-agent treatment of older patients (60 years or older) with previously untreated acute myeloid leukemia: Final results from a phase II study with three schedules.

6525 Background: Voreloxin, an anticancer quinolone derivative that inhibits topoisomerase II, has demonstrated clinical activity in ovarian cancer and acute myeloid leukemia (AML). Final results a...